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httpcense.Abstract It has been agreed that pulmonary hypertension should be determined by right heart
catheterization. However, being invasive and refused by many patients, echocardiography was
thought to be a reasonable substitute to determine a solid diagnosis of pulmonary arterial hyper-
tension. So fourteen patients with pulmonary arterial hypertension (class I) were studied by estimat-
ing pulmonary artery systolic pressure by both transthoracic echocardiography and right heart
catheterization using Swan-Ganz catheter. The patients were 4 males and 10 females with mean ages
about 46.25 ± 23.33 in males and 36.8 ± 11.63 in females (total mean age was about 39.5 ± 15.46
years). Mean value of the Echo SPAP: 82.79 + 34.25 mmHg, however in the RHC SPAP
76.21 + 24.97.
Comparing both clinical procedures via the Altman and Bland statistical method showed discrep-
ancy between both procedures. Results showed that the 6MWD (mean + SD 262.64 ± 85.98) is
signiﬁcantly correlated with the mean pulmonary arterial pressure only.
Conclusion: Echocardiography cannot be reliable alone in the proper decision making of diagno-
sis and management of pulmonary arterial hypertension.
ª 2013 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis.Open access under CC BY-NC-ND license.Introduction
Pulmonary hypertension is an hemodynamic and pathophysi-
ologic state that can be found in multiple clinical conditions299919; fax: +20 238371400.
(R.I.M. El-Korashy).
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://dx.doi.org/10.1016/j.ejcdt.2013.1[1]. Deﬁnitive diagnosis of pulmonary hypertension (PH) re-
quires an elevated mean pulmonary arterial pressure of
25 mmHg at rest measured by right heart catheterization
(RHC) [2]. Pulmonary hypertension was classiﬁed into ﬁve
classes according to the ESC/ERS 2009 [2], based on the Dana
point classiﬁcation 2008 [3]. Class1; pulmonary arterial hyper-
tension, included the following entities, (Idiopathic, Heritable
(Bone morphogenic protein receptor 2, activin receptor like
Kinase 1, endoglin, Unknown), drugs and toxins induced,
associated with (APAH) (Connective tissue diseases, human
immunodeﬁciency virus infection, portal hypertension,he Egyptian Society of Chest Diseases and Tuberculosis.
2.005
420 R.I.M. El-Korashy et al.congenital heart disease, schistosomiasis, chronic hemolytic
anemia), persistent pulmonary hypertension of the newborn).
In class 1 PAH, the core of the medical problem is the pul-
monary artery itself [4], where the different entities shared the
hemodynamic proﬁle of pre-capillary pulmonary hypertension
but presented a completely distinct clinical course [5]. More-
over, class 1 PAH could be treated by speciﬁc drug therapy tar-
geting the pulmonary circulation with different drugs that were
approved for use worldwide [6]. However, PAH was consid-
ered a rare disorder, with an estimated prevalence of 15–50 pa-
tients per 1 million of the population in Europe [7], because the
clinical picture was subtle [4]. This group was thought to be
under recognized and under diagnosed [8].
According to the deﬁnition of the ESC/ERS guidelines
2009, right heart catheterization was needed for accurate diag-
nosis of the pulmonary artery pressure [3]. Although RHC is
now a relatively safe procedure, it is invasive and impractical
to perform in patients for whom it is not clearly indicated.
Consequently there is a clear need for noninvasive procedures
that aid diagnosis and allow identiﬁcation of patients for
whom diagnostic RHC is warranted, because of a high likeli-
hood of the existence of PH [9].
Transthoracic echocardiography (TTE) is one such tool
and is widely available and safe. By using transthoracic echo-
cardiography, assessment of pulmonary artery systolic pres-
sure could be done by measuring maximum tricuspid
regurgitation velocity and applying modiﬁed Bernoulli equa-
tion to convert these values into pressure values;
PASP = (Vmax2 · 4) + RAP [10].
Rationale
The study at hand aimed at evaluation of whether echocardi-
ography can be considered alone as a reliable tool for diagno-
sis and follow up of pulmonary arterial hypertension without
the need for performing right heart catheterization.
Methodology
Twenty-ﬁve patients were provisionally diagnosed as pulmon-
ary hypertension class I according to the ESC/ERS 2009, forFigure 1 Comparison of the difference in pulmonary artery
systolic pressure estimated by RHC and Doppler echocardiogra-
phy against the mean of the two values ‘‘method of Altman and
Bland’’.proof by performing right heart catheterization. However
fourteen patients only consented for performing right heart
catheter, so the actual study population was 14 subjects.
For all, history taking, clinical examination, 6 min walk dis-
tance, arterial blood gases, pulmonary function test (spirome-
try) and transthoracic echocardiography were done.
Pulmonary artery systolic pressure was measured by both
echocardiography and right heart catheter. Plain chest X-ray
was done post catheterization to detect any complications.
Right heart catheterization was performed by using the
Swan-Ganz catheter, multilumen, balloon tipped, 110 cm long,
done under complete aseptic precautions. The route of entry
was via the right internal jugular vein.
Putting in consideration, the exclusion criteria for perform-
ing that right heart catheter: Tricuspid or pulmonary valve
mechanical prosthesis, right heart mass (thrombus and/or tu-
mor) and tricuspid or pulmonary valve endocarditis [11].
Results
The study population included 14 patients, 4 males and 10 fe-
males, with mean age 39.5 ± 15.46 years.
Study population echocardiographic mean EF:
69.79 ± 4.32, no clinical manifestations of left side heart
failure.
Right heart catheterization parameters
Mean value of the mean PAP: 46.21 ± 14.65 mmHg.
PCWP: less than 12 mmHg in all cases except 5 cases with
the diagnosis of bilharzial PAH and pulmonary aneurysmal
dilatation, where the wedging procedure failed.
Mean 6 MWD: 262.64 ± 85.98 (<300 m), 10 patients be-
low 300 m, and 4 patients above 300 m.
The plot showed that 1 case (7%) was out of standard devi-
ation, and 6 cases (43%), showed difference more than
10 mmHg between both procedures (see Fig. 1 and Table 4).
Discussion
This study included 25 patients provisionally diagnosed as
having pulmonary hypertension class 1 according to the
ESC/ERS, 2009 [2], waiting for conﬁrmation by performing
right heart catheter. However, 11 patients refused performing
the RHC, thus the study population was actually 14 sub-clas-
siﬁed as idiopathic, familial, and associated (Table 1). Starting
the drug therapy for those who refused performing the RHC
was an issue of debate, which raises the question of reliability
on echocardiography in determining the need to start speciﬁc
drug therapy.
The study population was 14 divided into 4 males and 10
females, a ratio that was almost known all over the world,
twice in females than males [12]. The reason for the higher fe-
male prevalence in PAH was never clariﬁed: some hypothesesTable 1 Subclasses of the cases.
Diagnosis Idiopathic Associated Familial
Number 5 8 (3 SLE and 5 Bilharzial) 1
Table 4 Correlation between Echo PASP and right heart
catheterization PASP in the study subjects (n= 14).
Echo PASP RHC PASP Pearson correlation test
Pearson correlation p value
82.79 ± 34.25 76.21 ± 24.97 0.718268 0.003809**
** Signiﬁcant correlation at p< 0.01.
Table 2 Comparison between the study subjects divided according to gender in the other parameters.
Males (n= 4) Females (n= 10) Independent samples t test
t p
Age 46.25 ± 23.33 36.8 ± 11.63 1.04 0.32
Echo E.F 69.25 ± 0.96 70 ± 5.14 0.28 0.78
Echo PASP 76.75 ± 22.41 85.2 ± 38.78 0.40 0.69
RHC PASP 79.75 ± 18.84 74.8 ± 27.84 0.32 0.75
mPAP 49.5 ± 15 44.9 ± 15.11 0.52 0.62
6 MWD 305 ± 78.73 245.7 ± 86.57 1.18 0.26
PaO2 69.5 ± 7.59 47.4 ± 13.66 3.01 0.011**
SaO2 93.75 ± 2.63 78.1 ± 16.59 1.83 0.092
E.F, ejection fraction; PASP, pulmonary artery systolic pressure; RHC, right heart catheter; mPAP, mean pulmonary artery pressure as
calculated from RHC; 6 MWD, 6 min walk distance; PaO2, arterial oxygen tension; SaO2, oxygen saturation.
** Signiﬁcant difference at p< 0.5.
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an X-linked locus in disease predisposition [13].
The mean age of study population was 39.5 ± 15.46 which
was congruent to the ﬁndings in different studies;
36.4 ± 15 years [14] and 37 years [15] While others stated that
the mean age was 53 ± 14 years [13,16].
The mean ejection fraction for the cases was within the nor-
mal range 69.79 ± 4.32. The known normal ranges 55–70%
and might even reach up to 77% [17].
The results showed that the mean 6 MWD of the study
population was <300 m, which signiﬁed poor prognosis [2]
and indicated that most of the patients present in late stages
of the disease; a ﬁnding that was also mentioned in other stud-
ies [12].
Although there was no statistical signiﬁcance between the
age difference in males and females, yet the mean age for af-
fected males was 46.25 ± 23.33 years while that for females
was 36.8 ± 11.63 years (Table 2). It was assumed that females
with pulmonary hypertension were of younger age at presenta-
tion than males due to the fact that testosterone actually has
pulmonary vasodilatory effect, thus offering a less severe form
of disease in men [18]. Some studies, demonstrated that estro-
gen exerts beneﬁcial effects on the pulmonary vasculature espe-
cially on treatment response [12]. However, it seems to
contradict the female predominance that is observed in PAH.
Thus, estrogen can be accused of being a cornerstone in the
pathobiology of the PAH, what is called ‘‘estrogen paradox’’
[19]; especially if estrogen was used as a replacement therapyTable 3 Correlation between different subjects’ parameters
(n= 14).
m PAP 6 MWD
Echo E.F P. correlation 0.118 0.268
Sig. (2-tailed) 0.689 0.354
Echo PASP P. correlation 0.726** 0.488
Sig. (2-tailed) 0.003** 0.077
RHC PASP P. correlation 0.836** 0.407
Sig. (2-tailed) 0.0001** 0.149
mPAP P. correlation – 0.58*
Sig. (2-tailed) – 0.029*
* Signiﬁcant correlation at p< 0.05.
** Signiﬁcant correlation at p< 0.01.[20]. The hemodynamic changes that occur during gestation,
labor and delivery, are poorly tolerated by PAH patients: this
may be reﬂected in earlier clinical deterioration [12]. Tofovic
hypothesized that unbalanced estradiol metabolism (i.e., a
shift toward the 16-hydroxylation pathway and/or reduced
activity of the 2-hydroxylation pathway, corresponding to ele-
vated estradiol and decreased methodroxy estradiol levels)
may be of inﬂuence in increasing the risk of PAH and/or exac-
erbates the progression of disease [21].
The Altman and Bland statistical method was performed to
evaluate the agreement between RHC and echocardiography
measurements of PASP, which showed disagreement in 43%
of the cases, with pressure difference more than 10 mmHg, de-
spite the presence of positive correlation between them (r 0.7, p
0.003). These ﬁndings were in concordant with Rich and
Coworkers, who found that echocardiography estimates of
PASP were determined to be inaccurate in 50.6% of patients
despite the presence of moderate correlation between echocar-
diography and RHC measurements of PASP (r 0.71, p< .01)
[22].
6 MWD was found to have a high statistical signiﬁcant cor-
relation with mPAP and not with PASP whether by echo or by
RHC (Table 3). 6 MWD is used in the follow up of PAH pa-
tients and considered to be an important prognostic determi-
nant [23]. It is used as a form of submaximal exercise testing
that is simple, reproducible, safe, inexpensive, and applicable
to everyday activities, sensitive to therapeutic interventions
and of prognostic relevance [24]. The PaO2 was found to be
signiﬁcantly lower in females than males (Table 2), which is
mostly due to the earlier clinical deterioration [12]. Oxygen
tension affection had been regarded as a cause rather than a
result in the pathophysiology of pulmonary arterial hyperten-
sion, mainly due to the hypoxic vasoconstriction response that
appears in pulmonary vasculature [25]. However from the re-
sults in the study at hand, hypoxia and pulmonary arterial
422 R.I.M. El-Korashy et al.hypertension showed a mutual affection that might be related
to the changes in pulmonary artery endothelium [26].
Conclusion
RHC is a procedure for diagnosis and follow up of the cases of
PAP, while echo is a simple non-invasive way for screening of
suspected patients. Thus, one cannot rely on echo alone for the
start of speciﬁc drug therapy for PAH.
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